CLAIMS

What is claimed is:

1. A capsule for use in an inhalation device wherein said capsule is filled with a dry powder comprising levodopa wherein the dry powder has a working density of between 0.01 g/cm^3 to 0.1 g/cm^3, and wherein the capsule's shell comprises hydroxypropyl methylcellulose (HPMC) and titanium dioxide;

wherein said capsule emits more powder comprising levodopa upon actuation of the inhalation device as compared to a capsule having a capsule shell that comprises HPMC and that is free of titanium dioxide; and

wherein said dry powder comprises 75% by weight or more of levodopa.

2. The capsule of claim 1, wherein said working density is between 0.02 g/cm^3 to 0.05 g/cm^3.

3. The capsule of claim 1, wherein said dry powder comprises from 2 to 8% of water by weight.

4. The capsule of claim 3, wherein said dry powder comprises from 5 to 6 % of water by weight.

5. The capsule of claim 1, wherein said capsule is a 00 size capsule.

6. The capsule of claim 5, wherein said dry powder comprises between 15 and 50 milligrams of levodopa.

7. The capsule of claim 6, wherein said dry powder comprises between 25 and 35 milligrams of levodopa.

8. The capsule of claim 1, wherein said dry powder further comprises a salt.

9. The capsule of claim 8, wherein said salt is sodium chloride.

10. The capsule of claim 8, wherein said dry powder further comprises a phospholipid.

11. The capsule of claim 10, wherein said phospholipid is dipalmitoylphosphatidylcholine (DPPC).

12. The capsule of claim 1, wherein the dry powder further comprises DPPC and sodium chloride.

13. The capsule of claim 1, wherein the FPF of the dry powder is 50% to 70% of the nominal dose.

14. The capsule of claim 1, wherein the capsule is filled with 30 to 50 milligrams of dry powder.

15. A capsule for use in an inhalation device wherein said capsule is filled with a dry powder comprising levodopa wherein the capsule's shell comprises hydroxypropyl methylcellulose (HPMC) and titanium dioxide.

16. The capsule of claim 15, wherein said dry powder comprises 75% by weight or more of levodopa.

17. The capsule of claim 15, wherein upon actuation of said powder from an inhalation device, the emitted dose of powder has an FPF (5.6) of 50 to 65%.

18. The capsule of claim 17, wherein upon actuation of said powder from an inhalation device, the emitted dose of powder has an FPF (5.6) of 50 to 55%.